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Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system. 
Proper function of DCs is crucial to elicit an effective immune response against pathogens 
and to induce antitumor immunity. Different members of the nuclear receptor (NR) family 
of transcription factors have been reported to affect proper function of immune cells. 
Nur77 is a member of the NR4A subfamily of orphan NRs that is expressed and has a 
function within the immune system. We now show that Nur77 is expressed in different 
murine DCs subsets in  vitro and ex vivo, in human monocyte-derived DCs (moDCs) 
and in freshly isolated human BDCA1+ DCs, but its expression is dispensable for DC 
development in the spleen and lymph nodes. We show, by siRNA-mediated knockdown 
of Nur77 in human moDCs and by using Nur77−/− murine DCs, that Nur77-deficient 
DCs have enhanced inflammatory responses leading to increased T cell proliferation. 
Treatment of human moDCs with 6-mercaptopurine, an activator of Nur77, leads to 
diminished DC activation resulting in an impaired capacity to induce IFNγ production by 
allogeneic T cells. Altogether, our data show a yet unexplored role for Nur77 in modifying 
the activation status of murine and human DCs. Ultimately, targeting Nur77 may prove to 
be efficacious in boosting or diminishing the activation status of DCs and may lead to the 
development of improved DC-based immunotherapies in, respectively, cancer treatment 
or treatment of autoimmune diseases.
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inTrODUcTiOn
Dendritic cells (DCs) are professional antigen-presenting cells. An important function of DCs is 
to instruct T cells to elicit immunity or tolerance (1, 2). Many factors contribute to the way DCs 
are shaped to elicit this function. Important factors are the type of pathogens that DCs encounter, 
such as bacteria or viruses, but also different microenvironmental factors in the tissues they reside 
in play a crucial role. DCs can be subdivided into classical or conventional DCs (cDC), interferon-
producing plasmacytoid DCs (pDC), and monocyte-derived DCs (moDC) each with their own 
specialized function (3–5). Because of their crucial role in the immune system, different subsets of 
DCs are exploited in immune therapy (6–15). So far, treatment success is limited and functional 
knowledge on how DCs initiate and stably steer antitumor responses in vivo is important (13–15). 
Identification of transcription factors that control DC function in both immunity and tolerance is 
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highly relevant, as these factors may serve as targets to modulate 
DC activity and function for the development of more successful 
DC-based immunotherapies.
Different members of the nuclear receptor (NR) family of 
transcription factors and their ligands have been shown to affect 
immune cells, including DCs (16–20). NRs are ligand inducible 
transcription factors having among others, steroid hormones or 
cellular metabolites as ligands. Several members have been well 
studied and were shown to play an immune modulatory role 
in DCs. Another group of NRs are so called “orphan” NRs for 
which no natural ligand has been identified yet, and the existence 
of ligands is disputed. The NR4A subfamily of orphan recep-
tors comprises three members, namely, Nur77 (NR4A1/TR3/
NGFI-B), Nurr1 (NR4A2/NOT/TINUR), and NOR-1 (NR4A3/
TEC/MINOR). Their activity appears to be primarily regulated at 
the expression level. The expression of the NR4As can be induced 
by a diverse range of signals, including fatty acids, stress, growth 
factors, cytokines, peptide hormones, and physical stimuli (21). 
Hallmark of this subfamily is to respond quickly to such changes 
in cellular environments and regulate gene expression in a ligand-
independent manner.
Members of this subfamily have been shown to be involved in a 
wide variety of pathological conditions. They have been shown to 
be dysregulated in multiple cancer types and promote or suppress 
tumors depending on specific cellular and tissue context, subcel-
lular localization, external stimuli, protein–protein interactions, 
and post-translational modifications in cancer cells [reviewed 
in Ref. (22)]. In addition, there is also increasing evidence that 
the NR4As play a role in neurodegenerative disorders such as 
Alzheimer’s and Parkinson’s disease by contributing to neuronal 
cell death via modulating mitochondrial function and ER stress 
by controlling intracellular levels of ROS and Ca2+ and regulating 
cellular autophagy (23–26). Also in autoimmune-driven central 
nervous system (CNS) inflammation, the NR4A NRs have been 
shown to play an important role (27, 28).
NR4A receptors have emerged to play an important role 
within the immune balance by transcriptional regulation of 
cytokines and growth factors in macrophages (29, 30). In 
addition, they have been shown to be involved in the negative 
selection of self-reactive T  cell clones in the thymus (31, 32) 
and are essential for thymic regulatory T cell development (33). 
Studies in Nur77−/− mice imply that Nur77 functions as a master 
regulator in the differentiation and survival of Ly-6C− monocytes 
(34, 35). Ly-6C+ and Ly-6C− monocytes that do express Nur77 
do not develop into moDCs (36). Thus, Nur77 expression is not 
required for the development into moDCs but is for differen-
tiation of Ly-6C+ monocytes into Ly-6C− “patrolling” monocytes 
(34, 36). Moreover, Nur77 has been shown to be involved in the 
polarization of macrophages toward an inflammatory phenotype 
important in atherosclerosis (37, 38).
We and others have recently reported expression of Nur77, 
Nurr1, and NOR-1 in murine DCs (39–43). Nurr1 has been 
shown to restrict the immunogenicity of bone marrow derived 
DCs (BMDCs) (43) and NOR-1 leads to activation-induced 
cell death in DCs (39), is important in DC migration (42), and 
is involved in TLR-mediated activation and gene expression of 
DCs (44). However, so far, the role of Nur77 expression in DCs 
remains elusive. We here set out to assess the expression kinetics 
and function of Nur77 in multiple subsets of murine and human 
DCs and its subsequent effect on inducing T  cell activation, 
revealing a function as activation modulator for Nur77 in DCs. 
Knowledge regarding the possibilities in altering the activation 




6- to 16-week-old C57BL/6J and Balb/C mice (Charles River), 
Nur77−/− mice (45) on a C57BL/6 background, and Nur77GFP 
mice [016607; C57BL/6-Tg(Nr4a1-EGFP/cre)820Khog/J; 
Jackson Laboratory] were housed under specific pathogen-free 
conditions in individually ventilated cage units at the Central 
Animal Laboratory (Nijmegen, The Netherlands). Standard labo-
ratory chow and sterile drinking water were provided ad libitum. 
All animal experiments were approved by the Radboud University’s 
Animal Welfare Body (Instantie voor Dierenwelzijn IvD) and the 
Animal Experiment Committee (DierExperimentenCommissie, 
RUDEC) that is recognized by the CCD (Central Authority 
for Scientific Procedures on Animals). The experiments were 
performed according to institutional, national, and European 
guidelines as stipulated in the Wet op de dierproeven and in the 
Dierproevenbesluit.
In Vitro generation of Murine Dcs
DCs were generated from murine BM isolated from the femur/
tibia of the mice. To obtain pDCs and cDCs, cells were cultured 
for 8–10  days (37°C, 10% CO2) in RPMI 1640 supplemented 
with 10% fetal calf serum (Gibco-BRL Life Technologies), 0.5% 
antibiotic–antimycotic (Gibco/Invitrogen), 1% ultra-glutamine 
(Lonza), 50 µM β-mercaptoethanol (Sigma-Aldrich), and 200 ng/ml 
human rFlt3L (PeproTech). Pure cell populations were isolated 
by labeling single cell suspensions with anti-SiglecH-FITC 
(eBiosciences) and anti-CD11c-APC antibodies for pDCs and 
cDCs, respectively. pDCs were positively sorted with anti-FITC 
microbeads, the negative fraction was subjected to positive selec-
tion with anti-APC microbeads (both Miltenyi Biotec, Germany) 
to obtain cDCs as described previously (40). CD103+ murine DCs 
were generated by culturing BM cells in RPMI 1640 supplemented 
with 10% FCS, 0.5% antibiotic–antimycotic, 1% ultra-glutamine, 
50 µM β-mercaptoethanol, 5 ng/ml mGM-CSF, and 200 ng/ml 
human rFlt3L, fresh medium was added at day 6, and cells were 
replated in fresh medium at day 9. Cells were harvested and used 
for experiments at day 14. The purity of the isolated DC subsets 
was ensured by flow cytometry.
Tumor induction
The transgenic cell line 9464D was derived from spontaneous 
tumors from TH-MYCN transgenic mice on C57BL/6 back-
ground and were a kind gift from Dr. Orentas (NIH, Bethesda, 
MD, USA). 9464D cells were cultured in DMEM containing 10% 
fetal calf serum, 1% non-essential amino acids, 0.5% antibiotic– 
antimycotic, and 50  µM β-mercaptoethanol. For induction of 
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tumors, 1 × 10e6 9464D cells were injected s.c. in 100 µl PBS on 
the right flank of the mice. Tumor growth was measured every 
3–4 days using calipers. Spleen and lymph nodes (LNs) of the mice 
were taken when the tumor was more than 5 mm in diameter.
Flow cytometry
To obtain single cells for flow cytometric staining, murine spleen 
was passaged over a 100  µm cell strainer, and murine LNs 
were incubated in serum-free medium containing collagenase 
(Worthington) and DNAseI (Roche), later supplemented with 
1 mM EDTA. In vitro generated human and murine DCs, and 
ex vivo isolated murine spleen and LN cells were stained using 
standard antibody staining protocols with antibodies listed in 
Table S1 in Supplementary Material. Cell viability was assessed 
by staining with fixable viability dye eFluor™ 450 (eBioscience). 
Samples were acquired on a FACS Verse (BD Bioscience), and 
data were analyzed with FlowJo software (Tree Star).
elisa
Human and mouse IL-6, TNFα, IL-12p70, and human IFNγ 
present in the supernatant of DC cultures was measured using 
the ELISA kit (Thermo Fisher) according to the manufacturers 
protocol.
Murine Type i iFn Bioassay
Type I IFN activity in the supernatant of murine pDCs was meas-
ured using L929 cells transfected with an interferon-sensitive 
luciferase construct (ISRE-L929) (46) with reference to a recom-
binant mouse IFN-β standard (Sigma). In short, pDC culture 
supernatants were added to ISRE-L929 IFN reporter cells and 
incubated for 4–6 h. Then, the cells were lysed in Passive Lysis 
Buffer (Promega), mixed with firefly luciferin substrate (Promega), 
and measured on a Victor3 Luminometer.
Mixed leukocyte reaction (Mlr)  
Murine Dcs
After 16–24 h of stimulation with 1 µg/ml CpGB (1668, Sigma-
Aldrich) or 4  µg/ml R848, pDCs, cDCs, or CD103+ DCs were 
washed and co-incubated with carboxyfluorescein diacetate suc-
cinimidyl ester (CFSE)-labeled allogeneic BalB/C T cells. T cells 
were isolated using the T cell isolation kit (EasySep). The cells 
were co-incubated for 3  days in round-bottom 96-well cluster 
plates (Corning). T  cell proliferation was measured by CFSE 
dilution by FACS.
generation of human Dcs
DCs were generated from cells isolated from buffy coats obtained 
from healthy volunteers (Sanquin, Nijmegen, The Netherlands) 
after written informed consent as per the Declaration of Helsinki. 
The study was approved by the Institutional Review Board of 
the Radboud University Nijmegen Medical Center, Commissie 
Mensgebonden Onderzoek. Peripheral blood mononuclear cells 
(PBMCs) were purified via Ficoll density gradient centrifugation 
(Lucron Bioproducts). moDCs were cultured as described previ-
ously (47). In short, plastic-adherent monocytes were cultured 
for 6 days in RPMI 1640 medium with 1% ultra-glutamine, 0.5% 
antibiotic–antimycotic, 10% (v/v) fetal calf serum, 300 U/ml IL4, 
and 450 U/ml GM-CSF (both Cellgenix). IL4 and GM-CSF were 
added again at day 3. To obtain fresh human myeloid dendritic 
cells (mDCs), CD14+ cells were depleted from the PBMCs 
followed by BDCA1+ DC isolation using the CD1c (BDCA1)+ 
Dendritic Cell Isolation Kit (Miltenyi Biotec). Purity of the freshly 
isolated mDCs was ensured by flow cytometry.
small interfering rna-Mediated 
Knockdown
For Nur77 silencing in human moDCs, the ON-TARGETplus 
SMARTpool NR4A1 (Dharmacon) containing four different 
Nur77 targeting siRNA oligos each 19  nt long was used. The 
irrelevant siRNA ON-TARGETplus Non-Targeting siRNA#1 
(Dharmacon) was used as control. moDCs were electroporated 
at day 4 as described before (47). Electroporated DCs were 
stimulated with 1 µg/ml LPS (Sigma) or 4 µg/ml R848 (Enzo Life 
Sciences) at day 6. Supernatant was taken 24 h later.
rna isolation and Quantitative Pcr
Total RNA was isolated and cDNA was synthesized as described 
before (47). mRNA levels for the genes of interest were deter-
mined with a CFX96 sequence detection system (Bio-Rad) using 
the Faststart SYBR green mastermix (Roche) with SYBR Green 
as the fluorophore and gene-specific oligonucleotide primers. 
The primers for human porphobilinogen deaminase (PBGD), 
IL-6, TNFα, and IL-12 (47) and murine PBGD, TLR7, and TLR9 
(40) were described previously. Other primers used (forward 
and reverse) are listed in Table S2 in Supplementary Material. 
Reaction mixtures and program conditions were used that were 
recommended by the manufacturer (Bio-Rad). Quantitative 
PCR data were analyzed with the CFX Manager V1.6.541.1028 
software (Bio-Rad) and checked for correct amplification and dis-
sociation of the products. As we described previously for human 
and murine DCs, mRNA levels of the genes of interest were 
normalized to mRNA levels of the housekeeping gene PBGD 
(19, 20, 40, 47, 48) and were calculated according to the cycle 
threshold method (49).
human Mlr
Human day 6 moDCs were pretreated with 1 or 10 µM 6-mer-
captopurine (6-MP) (Sigma) or vehicle control (DMSO) for 8 h, 
before o/n stimulation with 4 µg/ml R848. At day 7, the medium 
was replaced with fresh DC medium, and allogeneic peripheral 
blood lymphocytes were added to the DCs, in a ratio of 1:10 
(DCs:T cells) and cocultured for 144 h. Supernatant was taken 
for IFNγ measurements.
statistical analysis
In each experiment, at least three mice or human donors were 
used to be able to perform statistical testing. Each legend contains 
the information of the number of mice or human donors used 
including the statistics that was used to calculate significance. 
Statistical testing was performed using GraphPad Prism 5 soft-
ware (GraphPad, La Jolla, CA, USA). A P < 0.05 was considered 
significant.
FigUre 1 | Nur77 expression level in in vitro generated murine dendritic cells (DCs). (a) Plasmacytoid DCs (pDCs) and conventional DCs (cDCs) were sorted from 
FLT3L bone marrow cultures pooled from three mice per experiment and immediately lysed for RNA isolation (0 h) or stimulated for 3 h with a combination of R848 
and CpG. mRNA expression levels of Nur77 were detected by qPCR analysis. Data shown are the mean of three independent experiments ± SEM, two-tailed 
unpaired t-test: *P < 0.05; **P < 0.01; and ***P < 0.001. (B) In vitro generated cDCs, pDCs, or CD103+ DCs from Nur77GFP or control mice were stimulated for the 
indicated times with CpG, and GFP expression was determined by flow cytometry. Shown are the representative data of three mice. (c) Quantification of Nur77GFP 
expression in cDC, pDC, or CD103+ DC stimulated with CpG, LPS, or R848 for 0 or 3 h, presented as the geometric mean (MFI) ± SEM, two-way ANOVA with 
Sidak’s multiple comparisons test (n = 3). n.s., not significant; *P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001.
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resUlTs
nur77 expression and Function in  
Murine Dcs
As NR4A NRs are typical early response genes induced upon 
stimulation (29), we tested Nur77 expression in cDCs and 
pDCs 3 h after stimulation with a combination of the TLR7/8 
ligand R848 and the TLR9 ligand CpG. DCs were differentiated 
from murine BM in vitro with FLT3L as this reflects physiologic 
DC development and gives rise to a mixture of both cDCs and 
pDCs (50). pDCs were detected as CD11cposB220posSiglecHpos 
and cDCs were defined as CD11cposB220negSiglecHneg and were 
sorted and stimulated as described before (40) (Figure S1A in 
Supplementary Material). In agreement with its classification 
as early response gene, Nur77 mRNA levels were strongly 
upregulated after 3  h of stimulation in murine pDCs as well 
as cDCs compared with freshly sorted cells (0 h) (Figure 1A). 
To further assess Nur77 expression kinetics, we used BM cells 
from transgenic Nur77 reporter mice, where the induction of 
the Nur77 promoter drives GFP expression (Nur77GFP) (51). 
In line with its mRNA expression, cDCs and to a lesser extend 
pDCs up regulate Nur77GFP already after 3 h of stimulation with 
CpG (Figure 1B). In addition to FLT3L-derived BMDCs, we 
tested Nur77GFP in BMDCs differentiated into Batf3-dependent 
CD103+ DCs (CD11cposB220negCD103pos) when cultured with 
GM-CSF and FLT3L (52) (for gating strategy see Figure S1B 
in Supplementary Material). In CD103+ DCs, there is also 
already prominent expression of Nur77GFP after 3  h stimula-
tion with CpG (Figure  1B). Our data further show that the 
expression in cDCs was highest after CpG and LPS stimula-
tion, whereas the expression was less pronounced in response 
to R848. pDC and CD103+ DCs revealed highest expression 
of Nur77GFP after stimulation with CpG, compared with LPS 
and R848 (Figure  1C). These data indicate that in different 
types of in  vitro generated DCs, Nur77 expression is quickly 
induced upon stimulation with inflammatory ligands, and that 
the expression in response to TLR-specific agonists varies in 
different DC subsets.
nur77 Does not have a Major impact on 
the Development of Murine Dcs in spleen 
and lns
To test whether Nur77 expression is required for the develop-
ment of DCs, we investigated the presence of different DC 
subsets in spleen and LNs of WT and Nur77−/− mice. We 
observed a small but significant increase in the percentage 
of total CD11chiMHCIIhi DCs and in CD11b+ DCs (CD11chi 
MHCIIhiSirpαposCD24negCD115negCD4pos) of the spleen of 
Nur77−/− mice relative to WT mice (Figure 2A; Figure S2A in 
Supplementary Material). The number of CD8α+ spleen DCs 
(CD11chiMHCIIhiSirpαnegCD24posFLT3pos) was similar between 
WT and Nur77−/− mice. Also in the LNs, the presence of resident 
FigUre 2 | Absence of Nur77 expression does not have a major impact on dendritic cell (DC) development in the spleen and lymph nodes (LNs). % of DCs in  
(a) spleen and (B) inguinal LNs of WT or Nur77−/− mice. Shown are the means of pooled data of two independent experiments ± SEM for WT or Nur77−/− mice 
(n = 3). Two-tailed unpaired t-test: *P < 0.05; **P < 0.01; and ***P < 0.001.
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(CD11chiMHCII+) and migratory DCs (CD11c+MHCIIhi) was 
comparable (Figure 2B; Figure S2B in Supplementary Material). 
Also in a transplantable autologous TH-MYCN 9464D mouse 
model of neuroblastoma (53), we did not observe differences 
in the presence of the different subsets of DCs in the spleen or 
(non)draining LN (Figures S3A,B in Supplementary Material). 
These data indicate that Nur77 is dispensable for DC develop-
ment. Next, we tested the expression level of Nur77 in different 
DC subsets by analyzing DCs from the spleen and LNs from 
transgenic Nur77 reporter mice that express GFP upon activa-
tion of the Nur77 promoter. Nur77GFP was clearly expressed 
in CD11b+ spleen DCs. The expression in CD8α+ spleen DCs 
was less well defined and consisted of a population express-
ing Nur77GFP at a very low level and a population expressing 
Nur77GFP to a similar level as the CD11b+ DCs (Figures 3A,B). 
Resident DCs of inguinal and axillary LN expressed clear levels 
of Nur77GFP, in contrast to significantly lower expression in 
migratory DCs of these LN (Figures  3C,D). Mice bearing a 
neuroblastoma tumor showed a similar Nur77GFP expression 
pattern in DCs (Figures S3C,D in Supplementary Material) as 
in naïve mice. These data indicate that Nur77 expression does 
not have a major impact on the development and presence of 
different DC subsets in the spleen and LNs and that Nur77 is 
most abundantly expressed in CD11b+ spleen DCs and resident 
DCs of different LNs.
nur77-Deficient Murine Dcs have altered 
cytokine Production and T cell 
stimulatory capacity
To assess the functional role of Nur77 in different murine DC 
subsets, we investigated cytokine production by murine Nur77−/− 
BMDCs after stimulation with different inflammatory stimuli. 
We found that Nur77−/− cDCs produced significantly more IL-6, 
TNFα, and IL-12 upon CpG and R848 stimulation (Figure 4A). 
Nur77−/− pDCs showed increased production of IL-6 and IL-12 
upon R848 stimulation, whereas TNFα production was not 
affected. After stimulation with CpG, type I IFN production 
was much higher in Nur77−/− pDCs compared with WT pDCs 
(Figure 4B). CD103+ DCs showed a stronger response to CpG 
than to R848, revealing increased production of IL-6, TNFα, and 
IL-12 (Figure 4C). To rule out the possibility that the increase 
in cytokine production was (partly) mediated by enhanced TLR 
expression, we profiled TLR7 and TLR9 expression in these cells. 
FigUre 3 | Nur77 expression level in murine dendritic cells (DCs) ex vivo. (a) Ex vivo Nur77GFP expression in the different DC subsets in spleen, shown are the 
representative data of one out of three transgenic Nur77 reporter mice, where the induction of the Nur77 promoter drives GFP expression (Nur77GFP) mice.  
(B) Quantification of Nur77GFP expression in the different DC subsets in the spleen, presented as the relative Nur77GFP expression to control mice ± SEM, one-way 
ANOVA with Sidak’s multiple comparisons test (n = 3). (c) Ex vivo Nur77GFP expression in the resident and migratory DC subsets of the inguinal and axillary lymph 
nodes (aLN), shown are the representative data of one out of three transgenic Nur77 reporter mice. (D) Quantification of Nur77GFP expression in the resident and 
migratory DC subsets of the inguinal (iLN) and aLN, presented as the relative Nur77GFP expression to control mice ± SEM, two-way ANOVA with Sidak’s multiple 
comparisons test (n = 3): *P < 0.05; ***P < 0.001; and ****P < 0.0001.
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FigUre 4 | Cytokine production and T cell proliferation by murine Nur77−/− dendritic cells (DCs) are increased compared with WT DCs. Conventional DCs (cDCs) 
(a) and plasmacytoid DCs (pDCs) (B) were sorted from FLT3L bone marrow cultures or CD103+ DCs (c) derived from FLT3L/GM-CSF cultures were stimulated with 
CpG or R848, cytokine production was measured with ELISA. T cell proliferation (D) was measured after coculture of CpG or R848 stimulated cDCs, pDCs, or 
CD103+ DCs with BalB/C T cells and was measured as indicated by CFSE dilution on day 3. Data are shown as the mean ± SEM, two-way ANOVA with Bonferroni 
posttest (n = 3–6 different mice) (*P < 0.05; **P < 0.01; and ***P < 0.001).
7
Tel-Karthaus et al. Nur77 in DCs
Frontiers in Immunology | www.frontiersin.org August 2018 | Volume 9 | Article 1797
TLR7 and TLR9 expression was similar in WT and Nur77−/− 
cDCs, whereas TLR7 expression was reduced in Nur77−/− pDCs 
(Figure S4 in Supplementary Material). In addition to cytokine 
production, we investigated the T-cell stimulatory capacities 
for Nur77-deficient DCs. To this end, control, CpG, or R848 
stimulated DCs were added to an allogeneic MLR. All Nur77-
deficient DC subsets were significantly more potent in inducing 
T  cell proliferation than WT DCs upon stimulation with CpG 
(Figure 4D). These data indicate that Nur77 deficiency in DCs 
leads to enhanced cytokine production and subsequent increased 
T cell proliferation.
nur77 expression and Function in  
human Dcs
In addition to defining its expression and function in murine 
DCs we profiled Nur77 mRNA expression in human moDCs after 
stimulation with LPS and R848. In accordance with murine DCs, 
FigUre 5 | Nur77 mRNA expression in human dendritic cells (DCs). Human day 6 monocyte-derived dendritic cells (a) or freshly isolated BDCA1+ DCs (B) were 
stimulated for different time periods with LPS or R848. mRNA expression levels of Nur77 were detected by qPCR analysis. Expression levels shown are related to 
the housekeeping gene porphobilinogen deaminase (PBGD). Data shown are the mean ± SEM (n = 3–5 different donors).
8
Tel-Karthaus et al. Nur77 in DCs
Frontiers in Immunology | www.frontiersin.org August 2018 | Volume 9 | Article 1797
human moDCs quickly upregulated Nur77 mRNA expression 
and the expression remained stable for 24 h after stimulation with 
either LPS or R848 (Figure 5A). To investigate Nur77 expression 
in freshly isolated BDCA1+ blood myeloid DCs, purified BDCA1+ 
DCs were stimulated for different time periods with LPS or R848 
(Figure 5B). Compared with moDCs, freshly isolated BDCA1+ 
DCs had much higher expression levels of Nur77 expression 
under resting conditions. Stimulation with R848 led to a further 
increase of Nur77 expression, which diminished to lower levels 
16 h after stimulation. These data indicate that in different subsets 
of human DCs Nur77 is expressed with varying expression levels.
human nur77-Modified Dcs have altered 
cytokine Production and T cell 
stimulatory capacity
To test Nur77 function in human DCs, we silenced Nur77 expres-
sion in moDCs using a siRNA smartpool. Nur77 expression in 
moDCs decreased by 60–70% using siNur77 compared with 
control siRNA (siCTRL) (Figure  6A). These siNur77 targeted 
DCs had increased mRNA and protein expression of IL-6 and 
TNFα compared with siCTRL-treated DCs (Figures 6B,C), espe-
cially after R848 stimulation. Nur77-deficient DCs also showed 
enhanced IL-12 protein production. Profiling of TLR4, TLR7, 
and TLR8 expression (Figure S5 in Supplementary Material), 
revealed no change in TLR expression, indicating that the effect 
on cytokine production is not mediated via altered TLR expres-
sion. As NR4A family members have been reported to crosstalk 
with the NF-κB pathway (54), we investigated whether the 
enhanced cytokine production was dependent on NF-κB signal-
ing. Blocking NF-κB signaling with the NF-κB inhibitor BAY11-
7082 inhibited IL-6 and TNFα production in siNur77 DCs and 
siCTRL DCs to the same level (Figure 6D), indicating that the 
enhanced expression of IL-6 and TNFα was indeed dependent 
on NF-κB signaling. We next determined the expression of CD40, 
CD86, and CCR7 in siNur77 DCs. While siNur77 and siCTRL 
DCs show similar expression of the co-stimulatory markers 
CD40 and CD86, a significantly lower percentage of CCR7+ DCs 
were present in siNur77 DCs (Figure 6E). To further substantiate 
these data, we treated DCs with 6-MP, an activator of Nur77 
(55–59). Treating DCs with 6-MP before stimulation with R848, 
led to a dose-dependent decrease of IL-6 and IL-12 production, 
while TNFα levels were not altered (Figure 6F). No effect of 6-MP 
on cell viability could be detected (Figure S6 in Supplementary 
Material). In line with decreased IL-6 and IL-12 production, 
DCs pretreated with 6-MP were less capable of inducing IFNγ 
production by T cells in an allogeneic MLR (Figure 6G). These 
data show that human Nur77-modified moDCs have altered 
NF-κB-dependent inflammatory responses that are important in 
inducing T cell activation.
DiscUssiOn
Nuclear receptors have been shown to play a critical role in 
immune cell function, including members of the NR4A subgroup. 
However, the expression and function of Nur77 in different DC 
subsets has not been studied so far. We now show that Nur77 is 
expressed in different human as well as murine DC subsets. Its 
expression is rapidly upregulated upon stimulation with differ-
ent TLR ligands. Deficiency of Nur77 leads to enhanced NF-κB 
dependent cytokine production and T cell stimulatory capacity 
of DCs, while stimulation with the Nur77 activator 6-MP limits 
cytokine production by DCs and its capacity to stimulate alloge-
neic T cells.
Nur77 expression has been shown to be essential in the dif-
ferentiation and survival of Ly-6C− monocytes (34, 35), in the 
polarization of macrophages (37, 38, 60) and in the function and 
negative selection of T cells (31, 32). This NR is also expressed in 
infiltrating monocytes and monocyte-derived macrophages of the 
CNS that are important in experimental autoimmune encephalo-
myelitis (28) and in patrolling monocytes that control metastasis 
to the lung (61). We now show, in line with its classification as 
early response gene, that Nur77 expression is quickly upregulated 
in different human and murine DC subsets after stimulation with 
distinct TLR ligands in vitro. However, the expression levels in the 
different DC subsets and level of response toward diverse stimuli 
vary. We also found Nur77 expression in different subsets of DCs 
FigUre 6 | Knockdown or activation of Nur77 in human dendritic cells (DCs) alters DC function and T cell activation. Day 4 monocyte-derived dendritic cells 
(moDCs) were electroporated with a smartpool siRNA targeting Nur77 (siNur77) or a control siRNA (siCTRL). At day 6, cells were stimulated for 8 h with LPS, and 
Nur77 mRNA expression was detected by qPCR analysis (a), cytokine mRNA expression after 8 h of stimulation was measured by qPCR analysis (B), and  
cytokine levels were measured 24 h after stimulation with ELISA. (c) Electroporated moDCs were pretreated with Bay11-7082 and then stimulated with R848  
for 24 h. Cytokine levels were measured by ELISA. (D) CD40, CD86, and CCR7 expression was determined by FACS analysis. (e) moDCs were pretreated  
with 6-mercaptopurine (6-MP) and then stimulated with TLRL for 24 h. Cytokine levels were measured by ELISA. (F) moDCs were pretreated with 6-MP and 
subsequently stimulated with R848, T cell stimulatory capacity was measured in an allogeneic mixed leukocyte reaction by measuring IFNγ production by ELISA  
(g). Data shown are the mean ± SEM. Two-way ANOVA with Bonferroni posttest (n = 3–12 independent donors): *P < 0.05; **P < 0.01; and ***P < 0.001.
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in the spleen and LNs directly in naïve and in tumor-bearing mice 
ex vivo. Expression was more pronounced in the CD11b+ DCs of 
the spleen compared with CD8α+ DCs and higher in the resident 
than in the migratory DCs of the LNs. Previously, it has been 
shown that Nur77 is not required for the differentiation of Ly-6Chi 
monocytes into moDCs (36). We now also show that Nur77 defi-
ciency does not have a major impact on the presence of different 
DC subsets in the spleen and LN at steady state conditions as well 
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as mice bearing a neuroblastoma tumor. This confirms that in 
contrast to its expression in Ly-6C− monocytes, Nur77 expression 
is dispensable for the development of spleen and LN DCs.
Although most studies have reported that Nur77 has an anti-
inflammatory role in monocytes and macrophages (37, 38, 62), it 
has been shown that its overexpression in murine macrophages 
can lead to a pro-inflammatory response (63). Our data point 
towards an anti-inflammatory role in human and murine DC 
subsets. Nur77 deficiency in DCs leads to enhanced production 
of IL-6, TNFα, and IL-12 and subsequent enhanced T cell prolif-
eration, while Nur77 activation leads to reduced IL-6 and IL-12 
production and reduced T  cell activation. It has been hypoth-
esized that Nur77 acts to resolve inflammation in macrophages 
(38, 64) and based on our data we now suggest a similar role for 
Nur77 in DCs.
All NR4A family members, including Nur77, have been 
shown to modulate immune cell function via crosstalk to 
NF-κB (30, 38, 54, 65). Our data show that also in human 
DCs, Nur77 affects cytokine production by modulating the 
NF-κB pathway. It has been shown that Nur77 can affect 
the NF-κB pathway signaling in numerous ways (38, 63, 
65–68). Besides modulating phosphorylation of p65 Ser536 
and Ser529 in macrophages (38, 69), Nur77 has also been 
shown to directly interact with the p65 subunit of NF-κB (65, 66) 
and block p65 binding to DNA (65). Moreover, Nur77 can reg-
ulate TRAF6 auto-ubiquitination (67), important for NF-κB 
signal transduction (70–72). Future studies should reveal which 
mechanism underlies Nur77-mediated modulation of NF-κB 
signaling in DCs and whether different DC subsets or different 
inflammatory conditions involve specific ways of regulating 
NF-κB signaling.
While Nur77-deficient DCs show enhanced inflammatory 
responses, pretreating human DCs with 6-MP led to reduced 
inflammatory responses and a diminished capacity to induce 
IFNγ production by T  cells in an allogeneic MLR. 6-MP is a 
nucleic acid analog and has been shown to enhance Nur77 
transcriptional activity (55–59). Currently, it is being applied as 
an immunosuppressive drug for the treatment of several chronic 
inflammatory diseases such as inflammatory bowel disease, 
systemic lupus erythematosus, acute lymphoblastic leukemia of 
childhood, inflammatory myopathies, and rheumatoid arthritis 
and to prevent acute rejection in organ transplant patients (73–75). 
It has been shown that besides activating Nur77 (55, 56, 76) 6-MP 
can also activate the NR4A members Nurr1 (77) and NOR-1 
(76) and inhibit the GTPase proteins Rac1 and Rac2 (78, 79). 
Therefore, the effect observed in moDCs may be a combined 
effect of 6-MP on the function of either of these proteins. In 
addition to 6-MP many other pharmacological compounds have 
been generated to modulate Nur77 function. Among them are 
different C-DIMs [synthetic 1,1-bis(3′-indolyl)-1-(substituted 
phenyl)methane analogs] (80), cytosporone B and its structural 
analogs (81, 82), and TMPA (ethyl 2-[2,3,4-trimethoxy-6- 
(1-octanoyl)phenyl]acetate) (83). They have been shown 
to regulate Nur77 function by modulating Nur77-dependent 
 transactivation, influencing its expression levels, inducing 
nuclear export of Nur77 or affecting binding to other proteins 
(80–88). Many of these compounds have, as also shown for 
6-MP, also Nur77-independent actions (85, 89, 90). In cancer 
cells, neuronal cells, as well as different immune cells, it has been 
shown that Nur77 function depends on tissue context, subcel-
lular localization, external stimuli, protein–protein interactions, 
or post-translational modifications (22–26, 31, 32, 34, 35, 37, 
38, 60). How Nur77 function in DCs is exactly regulated upon 
specific immune stimuli and whether that is different in different 
DC subsets is currently unknown. Future studies should aim at 
fully elucidating whether specific stimuli in different subsets of 
DCs and under specific (pathological) conditions affect Nur77 
activation and thereby modulate DC function. More knowledge 
regarding the exact mechanism(s) of Nur77 activation in DCs 
will help to choose the best pharmacological compound tar-
geting specific actions of Nur77 in DCs. This will not only be 
important in optimizing current DC-based immunotherapies 
but also when more generally targeting Nur77 in different cell 
types and pathological conditions.
Interestingly, in tumor cells, the natural steroid Dendrogenin 
A has been shown to stimulate expression of Nur77 via binding 
to LXRβ and induce lethal autophagy (91, 92), opening up new 
perspectives for cancer treatment (93). Moreover, it has been 
shown that Dendrogenin A, in addition to inducing growth con-
trol and improve overall survival in mice, also induces immune 
cell infiltration, including DCs, in the tumor (94). As LXR has 
been shown to affect DC differentiation, maturation and migra-
tion (95–101), it is tempting to speculate that part of these effects 
are mediated via regulation of Nur77 expression, especially when 
DCs are stimulated with Dendrogenin A.
One striking observation is that the percentage of CCR7 
expressing human DCs was decreased in siNur77 treated moDCs. 
Interestingly, another member of the NR4A subfamily, NOR-1, 
has been shown to affect CCR7-dependent murine CD103+ DC 
migration from tissues to LNs in vivo (42). Nevertheless, we did 
not observe a similar effect on CCR7 expression in in vitro cul-
tured murine CD103+ DCs (data not shown). In agreement with 
Park et al., we did not find differences in the number of migra-
tory murine DCs present in the LN in Nur77−/− mice compared 
with WT mice, suggesting a less pronounced role for Nur77 in 
CCR7-dependent DC migration in mice. However, since NR4A 
family members are highly homologous proteins and can have 
redundant functions (102–104), it is also possible that the absence 
of Nur77 is compensated by NOR-1 in murine DCs.
Given that Nur77 modifies DC function with altered inflam-
matory responses, Nur77 may be an interesting therapeutic 
target to either boost or diminish the activation status of DCs 
in DC-based vaccination strategies in cancer or treatment of 
autoimmune diseases, respectively.
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